Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
Lan-Lan JiangPeng ZhangBing-Li LiuReng-Na YanLei YeJian-Hua MaFeng-Fei LiPublished in: BioMed research international (2021)
Our data indicate that dapagliflozin adjunct to insulin is a safe and effective therapy for improving glycemic variations, insulin sensitivity, and weight loss in newly diagnosed T2D patients.